ABOUT BIOMARIN
Founded 25 years ago, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery.
Learn More about BioMarin ⌃CAREERS AT BIOMARIN
Our focus on genetic disease gives us the opportunity to truly impact lives.
Learn More about careers with BioMarin ⌃
Patient & Community Support
Treatment is only the beginning.
We are committed to the communities we treat beyond the therapies
OUR PIPELINE
We maximize the impact of genetic innovation to develop transformative therapies.
We recently presented an update on our pipeline to the investor community. View the replay on our Investor Relations site.
View Now ⌃-
September 21, 2023BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
-
September 15, 2023BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
-
September 11, 2023BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York
-
September 6, 2023BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
-
September 5, 2023BioMarin to Participate in Three Upcoming Investor Conferences
-
August 30, 2023BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe
-
July 31, 2023BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
-
July 12, 2023BioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET